nsaids|非甾体类抗炎药的前世今生( 二 )
结语
从1899年NSAIDs原形药物阿司匹林的问世开始，我们见证了NSAIDs药物百年曲折的成长道路 。从有严重不良反应的保泰松，到不良反应相对减少的布洛芬、双氯芬酸钠，再到胃肠道风险显著降低但心血管风险增高的罗非昔布，直至如今胃肠道风险低且不增加心血管风险的特异性COX-2抑制剂塞来昔布，学者对NSAIDs的探索之路从未止步 。
参考文献
1. 徐建国等. 疼痛药物治疗学. 北京：人民卫生出版社. 2007: P131-133,137,259-260.
2. 姚中强, 于孟学, 韩淑玲. 非甾体抗炎药. 北京医学 2005;27(5):295-300.
3. 吴东海, 伍沪生. 非甾体抗炎药的发展史是一部迂回曲折的发展史. 中华医学信息导报 2005;20(10):14.
4. Antoniou K, Malamas M, Drosos AA. Clinical pharmacology of celecoxib, a COX-2 selective inhibitor. Expert Opin Pharmacother. 2007;8(11):1719-1732.
5. FDA RELEASES BLACK-BOX TEMPLATE FOR NSAIDS. https://www.fdanews.com/articles/73674-fda-releases-black-box-template-for-nsaids
6. Arber N, Eagle CJ, Spicak J, et al. Celecoxib for the prevention of colorectal adenomatous polyps. N Engl J Med. 2006;355(9):885-895.
7. ADAPT Research Group. Cardiovascular and Cerebrovascular Events in the Randomized, Controlled Alzheimer's Disease Anti-Inflammatory Prevention Trial (ADAPT). PLoS Clin Trials. 2006 Nov; 1(7): e33.
8. MacDonald TM, Hawkey CJ, Ford I, et al. Randomized trial of switching from prescribed non-selective non-steroidal anti-inflammatory drugs to prescribed celecoxib: the Standard care vs. Celecoxib Outcome Trial (SCOT). Eur Heart J. 2017;38(23):1843-1850.
9. Nissen SE, Yeomans ND, Solomon DH, et al. Cardiovascular Safety of Celecoxib, Naproxen, or Ibuprofen for Arthritis. N Engl J Med. 2016;375(26):2519-2529.
【nsaids|非甾体类抗炎药的前世今生】10. Chan FK, Lanas A, Scheiman J, et al. Celecoxib versus omeprazole and diclofenac in patients with osteoarthritis and rheumatoid arthritis (CONDOR): a randomised trial. Lancet. 2010;376(9736):173-179.
